Trial Profile
A phase I pilot trial of a multi-antigen loaded dendritic cell vaccine for the treatment of advanced renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2020
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary) ; Renal cancer vaccine (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 22 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.